Company
Celltrion INC
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
12
12 still marketed
Novel approvals
0
Approvals since 2021
11
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (12)
Newest FDA action first.
- Avtozma Tocilizumab-Anoh · 2026
- Eydenzelt Aflibercept-Boav · 2025
- Avtozma Tocilizumab-Anoh · 2025
- Truxima Rituximab-Abbs · 2018
- Steqeyma Ustekinumab-Stba · 2024
- Omlyclo Omalizumab-Igec · 2025
- Osenvelt Denosumab-Bmwo · 2025
- Yuflyma Adalimumab-Aaty · 2023
- Inflectra Infliximab-Dyyb · 2016
- Herzuma Trastuzumab-Pkrb · 2018
- Zymfentra Infliximab-Dyyb · 2023
- Vegzelma Bevacizumab-Adcd · 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.